Clinical Trials Logo

NK/T-cell Lymphoma clinical trials

View clinical trials related to NK/T-cell Lymphoma.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT05208853 Not yet recruiting - Hodgkin Lymphoma Clinical Trials

An Exploratory Clinical Study Evaluating the Safety and Efficacy of Anti CD30 CAR T Cells in Patients With CD30+ Relapsed/Refractory Lymphoma

Start date: February 10, 2022
Phase: Early Phase 1
Study type: Interventional

This is a single-center, open label, single dose study of anti CD30 CAR-T cells injection in treatment of patients with relapsed/refractory CD30+ lymphoma.

NCT ID: NCT04899414 Not yet recruiting - NK/T Cell Lymphoma Clinical Trials

Dexamethasone, Azacytidine,Pegaspargase and Tislelizumab for NK/T Cell Lymphoma

Start date: May 18, 2021
Phase: Phase 2
Study type: Interventional

The optimal first-line treatment for extra-nodal NK/T-cell lymphoma (ENKTL) has not been well-defined. This phase II study aimed to evaluate the efficacy and safety of Dexamethasone, azacytidine, Pegaspargase, Tislelizumab (DAPT) regimen for patients with newly diagnosed advanced stage ENKTL , non-upper aerodigestive tract NK/T- cell lymphoma(NUAT- NKTCL)and relapsed refractory NK/T cell lymphoma.

NCT ID: NCT03701022 Not yet recruiting - NK/T-cell Lymphoma Clinical Trials

PD1 Combined With Apatinib in Patients With Relapsed or Refractory NK/T Cell Lymphoma

Start date: October 20, 2018
Phase: Phase 2
Study type: Interventional

This is an open-label, single-center, nonrandomized, Phase 2 study to evaluate efficacy and safety of SHR-1210 combined with Apatinib in subjects with relapsed or refractory NK/T cell lymphoma.Efficacy will be assessed every 8 weeks according to 2014 Lugano criteria.Safety evaluations (both clinical and laboratory) are performed at baseline, before each study treatment, and throughout the study.